Researchers found that African-American patients with non-small cell lung cancer have similar rates of EGFR mutations, making targeted therapies like erlotinib a viable option. This discovery challenges previous assumptions about racial disparities in lung cancer treatment.
A novel nanoscale protein measurement technology, NIA, can be used in clinical trials to learn how drugs work and tailor therapy for each patient. The test distinguishes tumor cells from normal cells using protein profiles in the RAS and MAP kinase pathways.
Researchers have identified a single biomarker that may predict resistance to tivozanib in patients with kidney and breast cancer. The biomarker reflects the presence of white blood cells inside tumors and is associated with clinical activity.
Researchers identified 79 microRNAs linked to bladder cancer, showing promise for early detection through existing laboratory tests. The new method measures microRNA presence or absence in bodily fluids with high accuracy, comparable to current gold standard testing.
Researchers identified insulin-like growth factor 1 receptor (IGF-1R) overexpression in 25% of triple-negative breast cancers, correlated with gene amplification. IGF-1R blockade has been successful in sarcomas, and targeting this receptor may offer new therapeutic options for triple-negative breast cancer.
Targeting c-Met shows promise in treating HCC patients with positive tumors, according to a study. c-Met is overexpressed in metastatic liver cancer cells, driving growth and invasion.
Researchers have developed a biomarker panel that distinguishes prostate cancer from benign prostate disease and healthy tissue with high accuracy. The panel uses autoantibodies to identify proteins on the surface of cancer cells, enabling early diagnosis and potentially increasing cure rates.
A novel combination therapy of temozolomide and a Notch inhibitor has been shown to be highly effective in reducing tumor growth and recurrence in glioblastoma multiforme. This approach aims to target cancer stem cells, which are resistant to traditional therapies.
A new lab test developed by Japanese scientists can accurately predict imatinib resistance in chronic myeloid leukemia (CML) patients. The test measures protein levels and activity markers to identify resistant cells and determine the next therapeutic option, including dose escalation or combination therapy.
RG7204, a BRAF inhibitor, has shown significant preclinical activity against melanoma by inhibiting proliferation of tumor cell lines and inducing partial or complete tumor regression. The compound also improved survival rates without associated toxicity in preclinical models.
A preclinical study suggests combining targeted therapy against the BRAF/MAPK pathway with immunotherapy may improve durability of responses in treating melanoma. Researchers found that inhibiting the MAPK pathway resulted in increased antigen expression, leading to improved recognition by T-cells.
A study published in Cancer Research found that high calcium intake, even from non-dairy sources such as soy and green vegetables, may increase prostate cancer risk in Chinese men. The research, which analyzed data from over 27,000 men, showed a 25% increased risk of prostate cancer among those consuming higher amounts of calcium.
Researchers found that women with a breast density of 75% or higher have a four-to-five-fold increased risk of breast cancer. Decreases in breast density over time may be associated with lower breast cancer risk.
Research found a strong correlation between heavy alcohol use and shortened telomeres, increasing cancer risk. Telomere length was nearly half as long in heavy drinkers compared to non-abusers.
A prospective cohort study found that mid-life increase in body mass index (BMI) significantly increases the risk of postmenopausal breast cancer. Women who gained 5 kg/m2 or more between age 20 and study entry had a nearly twofold increased risk, with independent contributions from BMI gain before and after menopause.
Researchers found elevated EGFR levels in blood of women with breast cancer 17 months prior to diagnosis, increasing risk by 2.9-fold. This marker shows promise as an early detection biomarker for breast cancer.
A Phase I clinical trial demonstrated early signs of a strong safety profile and clinical activity for BBI608, a first-in-class cancer cell stemness inhibitor. Nine patients achieved stable disease for at least two months with early signs of tumor regression.
Researchers have evaluated a blood test that identifies patients with low-grade, low-stage prostate cancer who are at risk of needing treatment. The study found that a biomarker called Prostate Health Index was significant in predicting unfavorable biopsy conversion.
Researchers found that metformin decreases insulin levels and inhibits tumor growth in mice exposed to tobacco carcinogens. Metformin reduced lung tumor burden by 40-72% in treated mice.
Research suggests statin use may increase risk of developing benign colorectal tumors. The analysis found no benefit in tumor growth among patients using statins compared to those who never used them.
Researchers found that vitamin supplements reduced breast cancer risk by about 30 percent, while calcium supplements reduced it by 40 percent. Calcium supplements lost their protective effect once DNA repair capacity was accounted for.
Research reveals higher breast cancer rates among Latinas due to early diagnosis and poorer outcomes. Studies also show significant disparities in healthcare access and knowledge about screening practices among Mexican and Latina women living in the US.
Patient advocates and researchers at Vanderbilt Ingram Cancer Center presented an interactive game show on cancer research to increase awareness, particularly of clinical trials. The event resulted in a 20% increase in participants' knowledge and high engagement rates.
A recent study has found that breast cancer is affecting premenopausal women in Iraq, with a significant proportion presenting with advanced stage cancer. The study also highlights the importance of early detection and treatment, as only 32% of women detected a lump on self-examination sought medical advice within the first month.
Researchers have found that tumors can be treated with extreme heat or moderate heat using ultrasound techniques, showing promise for a new cancer therapy option. Hyperthermia has been shown to increase radiation damage and enhance chemotherapy treatments.
Researchers have found that a seaweed extract has an inhibitory effect on the growth of non-Hodgkin's lymphoma cell lines. The extract also showed a significant pattern of activity in genes linked to apoptosis, or cell death, in lymphoma cells.
Researchers found that microRNA-31 regulates the protein IFITM-1, which contributes to chemoresistance in ovarian cancer. Identifying this microRNA could lead to a therapeutic target for overcoming chemotherapy resistance.
A study published in Clinical Cancer Research found that obesity is a significant risk factor for poorer overall survival and death in patients with stage II or III colon cancer. Men with higher body mass indexes had a 35% increased risk of death compared to normal-weight patients.
Researchers have detected a novel oncolytic viral therapy against prostate cancer using the reovirus, showing safety and efficacy in early-stage patients. The study found that the virus induced cancer cell death without replicating in normal tissues, with minimal toxicity reported.
Researchers have found a new oncogenic signaling pathway by which arsenic may lead to adverse health effects, including bladder cancer. High levels of arsenic exposure are associated with high levels of Hedgehog activity, supporting the link between arsenic and increased cancer risk.
Researchers found that bitter melon extract significantly decreased proliferation and induced death in breast cancer cells. The study suggests that this extract may become a chemopreventive agent against breast cancer, but additional studies are needed to confirm its efficacy.
The Pancreatic Cancer Action Network and AACR awarded Zeshaan Rasheed a $600,000 grant to study cancer stem cells in pancreatic adenocarcinoma. The grant aims to develop novel therapies targeting cancer stem cell growth and spread.
The American Association for Cancer Research and International Association for the Study of Lung Cancer honored Dr. Paul A. Bunn Jr., M.D., for his contributions to lung cancer research. The conference emphasized the importance of translational research in improving lung cancer prognosis.
A new blood test has been developed to aid in lung cancer diagnosis and potentially reduce unnecessary invasive procedures. The test uses a 40-biomarker panel that correctly identified patients with lung cancer 88% of the time and those without it 79% of the time.
Researchers classified tumors into three growth patterns: destructive, alveolar, and papillary, which were independent predictors for overall survival, disease-specific survival, and disease-free survival. Patients with an alveolar growth pattern had a significantly higher risk of poor prognosis and reduced survival rates.
A study found that drinking green tea could reduce the risk of lung cancer in smokers, particularly those with specific genetic profiles. Among smokers, those who drank at least one cup of green tea per day had a significantly lower risk of lung cancer compared to non-green tea drinkers.
A study found that erlotinib dosing in lung cancer patients depends on their smoking status, with smokers requiring lower doses than non-smokers. Non-smokers were able to tolerate higher doses without developing grade 2 or 3 toxicity, while smokers reached a maximum tolerated dose of 300mg daily.
A recent study suggests that retreating patients with non-small cell lung cancer who initially responded to gefitinib treatment could lead to additional partial responses and stable disease. The overall disease control rate was 66.7 percent in the retreatment group, offering hope for patients who have failed initial chemotherapy.
A 93-gene signature associated with EGFR mutations in tumors from lung cancer patients was found to be a favorable prognostic marker for early stage lung cancer. The signature is also linked to drug sensitivity to erlotinib and gefitinib in non-small cell lung cancer cell lines.
Phase II study results of ASA404 showed improved overall survival in patients with squamous and non-squamous NSCLC compared to chemotherapy alone. The drug's unique mechanism of action inhibits tumor blood flow, providing a potential new treatment option for limited options.
A new study has found that patients with specific oncogenic rearrangements of the anaplastic lymphoma kinase (ALK) gene in their tumors respond significantly to an ALK-inhibitor therapy. The study suggests a paradigm shift in cancer drug development, allowing for more targeted treatments.
Researchers identified three microRNAs linked to chemoresistance in small cell lung cancer, affecting up to 15-30% of patients who are resistant to first-line therapy. The study provides new insights into predicting patient response to treatment and designing targeted therapies.
A Phase II study found celecoxib effective in reducing basal cell carcinoma development in patients with Gorlin syndrome, a rare genetic disorder. The drug showed promise as a chemoprevention therapy for this population.
Researchers found that pomegranate's ellagitannins can suppress estrogen production, inhibiting the growth of hormone-responsive breast cancers. The study suggests that consuming more pomegranates or exploring their juice as a potential preventive agent may have benefits.
A recent study found that black women with hormone receptor-positive breast cancer have worse disease-free and overall survival rates than women of other races. This disparity persists even after controlling for other factors such as medical care and comorbidities.
A study presented at the CTRC-AACR San Antonio Breast Cancer Symposium found that anti-estrogen therapy for breast cancer patients reduced their risk of dying from lung cancer. The research involved 6,715 women diagnosed with breast cancer between 1980 and 2003.
Research found moderate to heavy alcohol consumption increased breast cancer recurrence risk by 1.3-fold, with wine being the most popular choice among drinkers. Postmenopausal and overweight participants were more susceptible to the effects of alcohol on recurrence.
Researchers found that MRI coupled with mammography detected almost all cancers at an early stage in high-risk women, resulting in smaller cancer sizes and fewer advanced cases. This alternative screening method may convince healthcare providers to recommend yearly MRI and mammography over surgical removal of the breast.
Women with high BMI have poorer breast cancer prognosis, with increased risk of death and reduced treatment effectiveness. Researchers found that adjuvant treatment loses its effect more rapidly in obese patients.
Researchers found that xanthohumol, a flavonoid derived from hops, blocks the effects of testosterone and prevents prostate cancer. The study suggests that this compound may have beneficial effects in animals, reducing hormone signaling and gene expression in prostate tissue.